ERBB2 and neoplasm: In 2007, the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) released guidelines that defined as positive those cases with >30% of invasive tumor cells with a uniform intense membrane staining by IHC or HER2 /CEP17 of >2.2 for dual probes or >6 HER2 gene copies for single probes by FISH.